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http://dx.doi.org/10.1016/j.gmbhs.20Abstract The biochemical effects of chronic administration of efavirenz, which is commonly
used as part of highly active antiretroviral therapy for treatment of human immunodeficiency
virus (HIV) type 1, on the intracranial auditory relay centers [i.e., the inferior colliculus (IC)
and medial geniculate body (MGB)] of adult Wistar rats were carefully studied. Rats of both
sexes (n Z 30), with an average weight of 200 g, were randomly assigned into treatment
(n Z 15) and control (n Z 15) groups. Rats in the treatment group each received the recom-
mended daily dose of 600 mg/70 kg (1.71 mg/200 g) of body weight of efavirenz daily for 30
days, while the control group rats received an equal volume of distilled water alone daily
for 30 days. The rats were sacrificed after 30 days, and the IC and MGB were carefully removed
for further biochemical assays. These analyses indicated that levels of malonyldialdehyde
(MDA), a non-enzyme biomarker of oxidative stress, were significantly higher (p < 0.05)
whereas levels of superoxide dismutase (SOD) were significantly lower (p < 0.05) in treated
tissues than in control tissues. Chronic administration of efavirenz may therefore have an
adverse effect on the auditory sensibilities by affecting the IC and MGB of adult Wistar rats.
Copyright ª 2012, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
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86 J.O. Adjene et al.Introduction Materials and methodsEfavirenz is an antiretroviral drug that belongs to the class
of drugs called non-nucleoside reverse transcriptase
inhibitors used as part of highly active antiretroviral
therapy to treat human immunodeficiency virus (HIV) type
1.1 Efavirenz has been found to be effective in many
combination regimens for HIV treatment. It has been
combined successfully with nucleoside consisting of lam-
ivudine or emtricitabine plus abacavir, didanosine, stavi-
dine, tenofovir, or zidovudine to achieve virologic
suppression in a high percentage of recipients.2,3 Most
antiviral agents do not efficiently cross the bloodebrain
barrier or are actively transported out of the central
nervous system (CNS).4 Even after antiviral treatment that
successfully controls the virus in the treatment compart-
ments, the CNS may suffer continuing damage induced by
HIV infection.5 Efavirenz, however, can cross into the CNS
and spinal fluids and can be taken once a day without
regard to mealtimes.6,7
Some adverse effects in the CNS are commonly associ-
ated with efavirenz.8 Efavirenz intake has been reported to
be associated with several health problems, including
confusion, insomnia, abnormal and vivid dreams, dizziness,
and headaches.912 Nonetheless, efavirenz has emerged as
a cornerstone of highly active antiretroviral therapy regi-
mens. The side effect profile of the drug is generally
regarded as satisfactory. However, there are conflicting
study results in the medical literature as well as conflicting
reports from patients and physicians regarding neuropsy-
chiatry problems associated with efavirenz.13 Lipodys-
trophy, moderate or severe pain, abnormal vision,
arthralgia, asthenia, dyspnea, gynecomastia, myalgia,
myopathy, and tinnitus have been reported to be linked
with efavirenz.1
The inferior colliculus (IC) and medial geniculate body
(MGB) constitute the intracranial auditory relay centers.
The MGB is the target of ascending projections from the
IC and descending input from the auditory cortex; this is
the obligatory synaptic target in the thalamus for
hearing.14 The cerebral cortex strongly affects the MGB
through descending projections. These projections are
thought to consist primarily of small areas with slow
conduction velocities.15 It has been demonstrated that
auditory cortex neurons have great physiological plas-
ticity when rats are exposed to specific stimuli coupled
with concurrent stimulation of a forebrain subcortical
structure in the nucleus basalis. Observed changes have
included massive expansion of frequency-specific repre-
sentation.16 The IC is essential for normal hearing and for
the startle reflex.
Cortical structures such as the medial and lateral
geniculate bodies and the inferior and superior colli-
culi have higher glucose utilization than other struc-
tures.17 There is a correlation between functional
activity and metabolic rate much as in the visual and
auditory systems.17 Because efavirenz crosses the
bloodebrain barrier, it is relevant to investigate the
possible role of oxidative stress in efavirenz neuro-
toxicity in the intracranial auditory relay centers of
adult Wistar rats.Animals
The School of Basic Medical Sciences at the University of
Benin in Benin City, Edo state, Nigeria, granted approval for
the care and use of laboratory animals before the work
began. Thirty adult Wistar rats of both sexes with an
average weight of 200 g were randomly assigned into
control (n Z 15) and treatment (n Z 15) groups. The rats
were obtained and maintained in the Animal Holdings of the
Department of Anatomy, School of Basic Medical Sciences,
University of Benin, Benin City, Edo State, Nigeria. They
were fed with grower’s mash obtained from Edo Feeds and
Flour Mill Limited, Ewu, Edo State, Nigeria, and given water
ad libitum. Efavirenz was obtained from the President’s
Emergency Plan for AIDS Relief Unit, University of Benin
Teaching Hospital, Benin City, Edo State, Nigeria.
Drug administration
The rats in the treatment group received 1.71 mg of efa-
virenz per 200 g body weight, which is equivalent to the
recommended daily dose of 600 mg/70 kg. Efavirenz was
dissolved in distilled water and orally administered to the
treatment group rats with orogastric tube for 30 days, while
control rats received an equal volume of distilled water for
the same period. The body weights of both groups were
measured using a Mettler Toledo weighing balance before,
during, and after the period of treatment before being
sacrificed.
Dissection of the brain, IC, and MGB
The rats in both groups were sacrificed by cervical dislo-
cation, and the skull was quickly opened with the aid of
a pair of bone forceps to expose the brain. The IC and MGB
were carefully removed, weighed, and further subjected to
various biochemical assay techniques.
Preparation of samples
The samples (of IC and MGB) from the experimental animals
were removed and homogenized in a mortar and pestle
with a pinch of acid washed sand and a total of 5 mL normal
saline (0.9%) added sequentially during the homogenization
process. The homogenates were centrifuged at 3500 rpm
for 5 minutes with the aid of a centrifuge. The clear
supernatants were then collected using a micropipette,
transferred into an empty specimen container, and refrig-
erated until needed for the assays.
Superoxide dismutase assay
The superoxide dismutase (SOD) activities in these tissues
were determined using the method described by Misra and
Fridovich.18 An aliquot (0.4 mL) of the supernatant was
added to 5 mL of 0.05M carbonate buffer (pH 10.2) equili-
brated in the spectrophotometer for 2e3 minutes. The
reaction was then initiated by the addition of 0.6 mL of
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buffered supernatant mixture, which was quickly mixed by
inversion and the absorbance taken. The reference cuvette
contained 5 mL carbonate buffer, 0.6 mL substrate, and
0.4 mL distilled water. The increase in absorbance at
420 nm due to the adenochrome formed was monitored
every 30 seconds for 120 seconds. One unit of SOD activity
was given as the amount of SOD necessary to cause 50%
inhibition of the auto-oxidation of adrenaline to adeno-
chrome during 120 seconds. It was allowed to equilibrate
before the addition of adrenaline solution and then read
immediately. The absorbance was measured at 420 nm.Catalase assay
The method of Cohen et al19 was adopted for the catalase
assay. Aliquots of the homogenate supernatant (0.5 mL)
were added into ice cold test tubes while the blank con-
tained 0.5 mL distilled water. The reaction was initiated
by adding sequentially, at fixed intervals, 5 mL of cold
30 mM hydrogen peroxide followed by thorough mixing by
inversion. The test samples and the blank were taken one
at a time, and 7 mL of 0.01M potassium permanganate was
added and then mixed twice by inversion and absorbance
at 480 nm. Each sample was read within 30e60 seconds.
The spectrophotometer standard was prepared by adding
7 mL of 0.01M potassium permanganate to a mixture of
5.5 mL of 0.05M phosphate buffer with pH 7.0 and 1 mL of
6M tetraoxosulfate VI acid solution. The spectrophotom-
eter was zeroed with distilled water and the activity of the
enzyme was then estimated.Peroxidase assay
The peroxidase assay was based on the method of Chance
and Maehly.20 First, 0.4 mL of the sample homogenate was
added to clean test tubes, followed by the addition of
5 mL phosphate buffer and 5 mL hydrogen peroxide, then
by 3 mL distilled water. Finally, 5 mL pyrogallol was
added, and the absorbance was measured at 430 nm. The
blank was prepared by the addition of 0.45 mL phosphate
buffer, followed by 5 mL hydrogen peroxide. Then, 3 mL
distilled water was added, and finally, pyrogallol was
added to zero the spectrophotometer before taking the
absorbance of the test.Malonyldialdehyde assay
Lipid peroxidation was estimated in terms of thio-
barbituric acid reactive species (TBARS) using malo-
nyldialdehyde (MDA) as the standard according to the
method of Beuge and Aust.21 First, 1.0 mL of the sample
extract was added to 2.0 mL TCAeTBAeHCL reagent [15%
(w/v) TCA, 0.375% (w/v) TBA and 0.25N HCL]. The
contents were boiled for 15 minutes, cooled, and
centrifuged at 10,000g to remove precipitate. The
absorbance was read at 535 nm, and the malonyldialde-
hyde concentration of the sample was calculated using
the extinction coefficient of 1.56  105 M1 Cm1.Glucose-6-phosphate dehydrogenase assay
This assay was based on the method of Hess et al.22
Glucose-6-phosphate dehydrogenase (G-6-PDH) activity
was determined by the measurement of the rate of absor-
bance change at 340 nm due to the reduction of NAPþ.
Aliquots of the homogenate supernatant (15 mL) were
added into test tubes while the blank contained 15 mL
distilled water. The reaction was initiated by adding
sequentially, at fixed intervals, 1000 mL of reagent R1
(31.7 mmol/l triethanolamine buffer, pH 7.6, and
3.2 mmol/L EDTA) followed by the addition of 30 mL of
reagent R2 (0.34 mmol/L NADP), and then followed by
thorough mixing and incubation for 5 minutes at 37 C. The
test samples and the blank were taken one at a time, and
15 mL of reagent R3 (0.58 mmol/L glucose-6-phosphate) and
15 mL of reagent R4 (digitonin) were added and mixed twice
by inversion, and the absorbance was read at 340 nm within
0e3 minutes. The spectrophotometer was zeroed with
distilled water, and the activity of the enzyme was
estimated.Lactate dehydrogenase assay
This assay was based on the method of Weisshaar et al.23
Lactate dehydrogenase (LDH) enzyme activity was deter-
mined by the measurement of the rate of absorbance
change at 340 nm due to the reduction of NADHþ. Aliquots
of the homogenate supernatant (0.02 mL) were added into
test tubes while the blank contained 0.02 mL distilled
water. The reaction was initiated by adding sequentially, at
fixed intervals, 1.0 mL of the reagent, and the absorbance
was read at 340 nm within 0e3 minutes. The spectropho-
tometer was zeroed with distilled water, and the activity of
the enzyme was estimated.Statistical analysis
The results were calculated for mean and standard error of
means. The results from the various assays were analyzed
using one-way analysis of variance for a significance level of
p > 0.05.Results
The results of the biochemical assays were calculated; the
results are shown in Table 1, and presented as bar charts in
IC (Fig. 1) and MGB (Fig. 2), respectively. The activities of
SOD and LDH in the efavirenz-treated MGBs and ICs
decreased significantly (p < 0.05) compared to those of the
control group. The activities of catalase were found to
decrease in the efavirenz-treated IC and increase in the
efavirenz-treated MGB, but these differences were not
statistically significant (p < 0.05) in comparison with the IC
and MGB samples of the control group. The glutathione
peroxidase activities, MDA, and G-6-PDH levels increased
significantly (p < 0.05) in efavirenz-treated ICs and MGBs as
compared to ICs and MGBs of the control group.
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Figure 2 Bar chart showing biochemical assay results for the
medial geniculate body (MGB) of the animals. G6PDZ glucose
6-phosphate dehydrogenase; GPx Z peroxidase;
LDH Z lactate dehydrogenase; MDA Z malonyldialdehyde;
SOD Z superoxide dismutase.
Table 1 Biochemical assay results for the IC and MGB of
the animals.
Biochemical effect
Brain tissue
IC MGB
SOD (units/L)
Control 5.99  0.06* 6.53  0.03*
EFV 1.22  0.02* 1.15  0.02*
Catalase (units/L)
Control 0.0145  0.0005 0.0120  0.001
EFV 0.0125  0.0005 0.0135  0.0005
GPx (units/L)
Control 0.685  0.005* 0.665  0.015*
EFV 0.730  0.010* 0.795  0.005*
MDA (units/L)
Control 0.913  0.001* 0.935  0.006*
EFV 1.070  0.001* 1.077  0.002*
G-6-PDH (U/L)
Control 0.0020  0.001* 0.0015  0.001
EFV 0.0035  0.005* 0.003  0.000
LDH (Units/L)
Control 0.99  0.06* 0.53  0.03*
EFV 0.72  0.02* 0.15  0.02*
*Significant (p < 0.05).
EFV Z efavirenz; G-6-PDH Z glucose- 6-phosphate dehydro-
genase; GPxZ glutathione peroxidase; ICZ inferior colliculus;
LDH Z lactate dehydrogenase; MDA Z malonyldialdehyde;
MGB Z medial geniculate body; SOD Z superoxide dismutase.
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Efavirenz has been reported to be associated with a variety
of health problems, including problems related to the CNS.
Common among such problems are confusion, insomnia,
abnormal and vivid dreams, dizziness, and headaches.912
It has been suggested that chronic administration of efa-
virenz may also affect the weight and microanatomy of the
brain and colliculi in adult Wistar rats.2426 However, the
underlying mechanism involved in this toxicity is not wellInferior colliculus
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Figure 1 Bar chart showing biochemical assay results for the
inferior colliculus (IC) of the animals. G6PD Z glucose 6-
phosphate dehydrogenase; GPx Z peroxidase; LDH Z lactate
dehydrogenase; MDAZ malonyldialdehyde; SODZ superoxide
dismutase.understood. This study was aimed at investigating the
possible role of oxidative stress in efavirenz neurotoxicity
in the intracranial auditory relay centers of adult Wistar
rats. It was hypothesized that oxidative stress may be
a biochemical mechanism for the toxicity. Thus, oxidant
biomarkers (MDA and SOD) and antioxidant enzymes have
been implicated in this investigation.
The results of this experiment showed that oxidative
stress measured in terms of MDA was found to increase
significantly (p < 0.05) in all treated tissues under investi-
gation as compared with their parallel controls. Concomi-
tantly, the activity of SODwas found to decrease significantly
(p < 0.05) in the treated tissues compared with their
controls. These results demonstrate that efavirenz exerts its
toxic effects by promoting oxidative stress in the IC and MBG
of adult Wistar rats. The observation reported in this
experiment is consistent with the studies carried out by
Otitoju et al,27 who investigated the possibility of an oxida-
tive mechanism in insecticide toxicity and reported that the
oxidative stress increased in all experimental groups.27
Antioxidant levels are lower whereas pro-oxidant poly-
unsaturated fatty acid levels are higher in the CNS relative
to other tissues. Therefore, the CNS is exceptionally at risk
of oxidative damage. Antioxidant enzymes such as cata-
lase, glutathione peroxidase, G-6-PDH, LDH, and SOD are
responsible for the brain’s basic functions, both physical
and cognitive.28e30 It is known that the activities of anti-
oxidant enzymes are significantly modified in the CNS
during intoxication, when a decrease in activity may indi-
cate oxidative modification of the enzymatic proteins.
Other viable explanations associated with the decreased
activities of antioxidant enzymes may include a decrease in
the synthesis rate. In this study, catalase, G-6-PDH, gluta-
thione peroxidase, and LDH demonstrated inconsistent
levels across the ICs and MGBs of adult Wistar rats. An
increase in the activity of these antioxidant enzymes may
often be due to an adaptive response to excess free radi-
cals. Furthermore, catalase may be unreliable in this
respect because the decrease in its activity may be due to
an enhancement of protein synthesis as a confounding
factor.28 There was also a confounding factor for G-6-PDH
Biochemical effect of efavirenz on auditory relay centers 89that is capable of inactivating the enzyme.29 These con-
founding factors may explain the inconsistency in the
relative levels of these enzymes observed in this study. It is
known that the metabolic products of efavirenz include
hydroxylated products and their O-glucuronide, N-glucuro-
nide, and sulfate conjugates among others.31 It is recom-
mended that further studies review the metabolic products
of efavirenz to determine which of them have pro-oxidant
properties, with a view to determining how to manage
the oxidative damage resulting from efavirenz therapy.
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